吉非替尼治疗非小细胞肺癌患者的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Gefitinib in the treatment of patients with non-small cell lung cancer(NSCLC).Methods A total of 80 patients with NSCLC admitted to our hospital from March 2015 to May 2016 were enrolled in this study.They were divided into the control group and the the observation group according to a random number table method,40 cases in each group.The control group was treated with GP regimen,Gemcitabine combined with Cisplatin regimen,while the observation group was treated with Gefitinib.The epidermal growth factor receptor(EGFR)mutations in the two groups were compared.The keratin 19(CYFRA 21-1)and carcinoembryonic antigen(CEA)levels after treatment,and median survival time,quality of life,and therapeutic effect of the two groups were compared.Results The mutation rate of the observation group was significantly lower than that of the control group(P＜0.05).The levels of CYFRA 21-1 and CEA in the observation group were lower than those of the control group (P＜0.05).The survival time of the observation group was longer than that of the control group(P＜0.05).The 1-year and 2-year survival rates of the observation group were both higher than those of the control group(P＜0.05).The effectiveness rate of disease treatment in the observation group was significantly higher compared with that of the control group (P＜0.05).Conclusion In NSCLC patients with markedly elevated CEA and CYFRA 21-1 levels,Gefitinib treatment can effectively reduce EGFR mutation rate,reduce tumor marker levels,prolong patient′s survival time,and improve the clinical therapeutic effect.

Key words： Gefitinib Carcinoembryonic antigen Keratin 19 Non-small cell lung cancer Epeidermal growth factor receptor mutation rate Survival

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Chao
	JIN E
	TIAN Hong

Cite this article:

HUANG Chao,JIN E,TIAN Hong. Clinical effect of Gefitinib in the treatment of patients with non-small cell lung cancer[J]. 中国当代医药, 2019, 26(2): 64-67.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I2/64

[1]	王群慧，郑华，胡范彬，等.伴有EGFR突变的非小细胞肺癌血清CYFRA21-1和CEA水平与EGFR-TKIs的疗效关系[J].中国肺癌杂志，2016，19（8）：550-558.
[2]	韩涛，杨晓丹，谢晓冬，等.DC-CIK细胞联合EGFR TKI治疗EGFR突变阳性进展期非小细胞肺癌的疗效[J].中国肿瘤生物治疗杂志，2016，23（3）：408-412.
[3]	Zhou G，Zhang F，Guo Y，et al.miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1[J].Biomed Pharmacother，2016，5（85）：113-119.
[4]	Pakkala S，Ramalingam SS.Epidermal growth factor receptor mutated advanced non-small cell lung cancer：a changing treatment paradigm[J].Hematol Oncol Clin North Am，2017，31（1）：83-99.
[5]	林景辉，何志勇，林动，等.EGFR-TKI治疗EGFR突变的Ⅳ期NSCLC的临床观察[J].齐齐哈尔医学院学报，2016，37（15）：1881-1885.
[6]	赵钊，陈盼盼，张萍.NSCLC患者EGFR基因突变与血清肿瘤标志物相关性分析研究[J].中国卫生检验杂志，2014，24（15）：2217-2222.
[7]	王娜，郑清，孙成铭，等.非小细胞肺癌EGFR基因突变的表现及其与肿瘤标记物的相关性[J].现代肿瘤医学，2016，24（19）：3053-3056.
[8]	林顺欢，江冠铭，刘淳，等.贝伐珠单抗联合EGFR-TKI治疗EGFR外显子19或21突变晚期非小细胞肺癌的疗效差异[J].新医学，2016，47（7）：472-476.
[9]	黄宇筠，袁润强，陈应智，等.非小细胞肺癌基因突变与扩增的比较及其与血清水平的关系[J].分子诊断与治疗杂志，2015，7（1）：22-26.
[10]	肖何，王阁，王东，等.非小细胞肺癌血浆 EGFR突变与肿瘤标志物水平的关系[J].第三军医大学学报，2013，35（14）：1520-1523.
[11]	刘宁，张康，颜淑霞，等.非小细胞肺癌EGFR基因突变及与疗效的相关性研究[J].现代肿瘤医学，2013，21（2）：330-333.
[12]	李焕焕，马晓平，林芷伊，等.首次复发NSCLC患者血清CEA水平与EGF-TKI疗效相关性分析[J].中华肿瘤防治杂志，2015，22（4）：281-284.
[13]	张连民，郝李刚，张华，等.血清癌胚抗原与非小细胞肺癌患者EGFR突变的关系及其对预后的影响[J].中国肿瘤临床，2014，41（17）：1075-1079.
[14]	钟文昭，李巍，董嵩，等.血清CEA水平在EGFR-TKI治疗非小细胞肺癌的应用价值[J].临床与病理杂志，2015，35（6）：951-959.
[15]	Huang A，Li R，Zhao J，et al.Epidermal growth factor receptor （EGFR）-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced nonsmall cell lung cancer patient with EGFR sensitive mutation[J].Thorac Cancer，2016，7（5）：614-618.